» Articles » PMID: 16213628

Parkin-mediated Lysine 63-linked Polyubiquitination: a Link to Protein Inclusions Formation in Parkinson's and Other Conformational Diseases?

Overview
Journal Neurobiol Aging
Publisher Elsevier
Date 2005 Oct 11
PMID 16213628
Citations 70
Authors
Affiliations
Soon will be listed here.
Abstract

Most, if not all, neurodegenerative diseases are marked by the presence of ubiquitin-positive protein inclusions. How proteins within these inclusion bodies escape proteasomal degradation despite being enriched with ubiquitin remains a conundrum. Current evidence suggests a relationship between proteasomal impairment and inclusion formation, a persuasive explanation for the inability of the cell to remove ubiquitinated protein aggregates. Alternatively, the formation of ubiquitin-enriched inclusion may be uncoupled from the proteasome. Supporting this, we recently uncovered a novel, proteasomal-independent, catalytic activity for the Parkinson disease (PD)-linked ubiquitin ligase, parkin, that significantly enhances the formation of Lewy body (LB)-like inclusions generated in cultured cells by the co-expression of alpha-synuclein and synphilin-1. This unique activity of parkin mediates a non-classical, lysine (K) 63-linked ubiquitin multichain assembly on synphilin-1 that is distinct from the classical, degradation-associated, K48-linked ubiquitination. Interestingly, two other PD-linked gene products, alpha-synuclein and UCHL1, have recently also been associated with K63-linked ubiquitination. Inclusive of parkin, there are therefore now three PD-related gene products that are known to potentiate K63-linked ubiquitination, thus signalling an important functional relationship between this unique mode of ubiquitin tagging and PD pathogenesis. Mechanistically, the involvement of a "non-degradative" mode of ubiquitination in protein inclusion formation is an attractive explanation for how proteins are seemingly stabilized within inclusions.

Citing Articles

Ubiquitin-Proteasome-Mediated Protein Degradation and Disorders of the Central Nervous System.

Hegde A, Timm L, Sivley C, Ramiyaramcharankarthic S, Lowrimore O, Hendrix B Int J Mol Sci. 2025; 26(3).

PMID: 39940735 PMC: 11817509. DOI: 10.3390/ijms26030966.


Protein modification in neurodegenerative diseases.

Ramazi S, Dadzadi M, Darvazi M, Seddigh N, Allahverdi A MedComm (2020). 2024; 5(8):e674.

PMID: 39105197 PMC: 11298556. DOI: 10.1002/mco2.674.


Identification of metabolites reproducibly associated with Parkinson's Disease via meta-analysis and computational modelling.

Luo X, Liu Y, Balck A, Klein C, Fleming R NPJ Parkinsons Dis. 2024; 10(1):126.

PMID: 38951523 PMC: 11217404. DOI: 10.1038/s41531-024-00732-z.


Exploring the Role of Ubiquitin-Proteasome System in the Pathogenesis of Parkinson's Disease.

Zhao Y, Lin M, Zhai F, Chen J, Jin X Pharmaceuticals (Basel). 2024; 17(6).

PMID: 38931449 PMC: 11207014. DOI: 10.3390/ph17060782.


Is There a Place for Lewy Bodies before and beyond Alpha-Synuclein Accumulation? Provocative Issues in Need of Solid Explanations.

Lenzi P, Lazzeri G, Ferrucci M, Scotto M, Frati A, Puglisi-Allegra S Int J Mol Sci. 2024; 25(7).

PMID: 38612739 PMC: 11011529. DOI: 10.3390/ijms25073929.